Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China's Aida Pharmaceuticals has expanded its drug development pipeline with the acquisition of three new drugs - one with potential to treat immune disorders and two anticancer drugs.
Subscribe to our email newsletter
The addition of these new drugs swells Aida’s product pipeline from four to seven developmental drugs. The three drugs are either being evaluated for pre-clinical trials or in various early stages of applied research.
The drugs include – Prodigiosin, a naturally occurring red pigment, currently in pre-clinical trials for the treatment of pancreatic cancer, an anti-CD86 monoclonal antibody to treat immune diseases and an anti-CTLA-4 monoclonal antibody to inhibit tumor growth.
“Each of these drugs represents a unique scientific opportunity to improve healthcare for critical patients. Physicians and patients are demanding non-invasive biochemical therapies; Aida Pharmaceuticals has the knowledge and capacity to develop and deliver these therapies over the long-term,” stated Jin Biao, Aida Pharmaceuticals’ chairman.